For over 20 years, we have been manufacturing ibuprofen at our FDA-audited, cGMP-certified site in Bishop, Texas – offering a portfolio that delivers unparalleled quality, safety and security of supply. Our wide range includes innovative compounds that slash production time and costs, and faster-acting products that provide rapid pain relief. What’s more, customers benefit from the industry’s most eco-efficient production process, which minimizes waste by avoiding chromium and aluminum salts.
Ibuprofen from the world leader
Leading In Sustainable Ibuprofen Production
BASF’s ibuprofen production process is an innovative, efficient technology that has revolutionized bulk pharmaceutical manufacturing. It provides an innovative solution to a prevalent problem commonly encountered in bulk API synthesis. Large volumes of aqueous wastes (often containing chromium salts) normally associated with such manufacturing are virtually eliminated. The anhydrous hydrogen fluoride catalyst/solvent is recovered and recycled. Furthermore, no other solvent is needed in any of the reaction steps, simplifying product recovery and minimizing fugitive emissions. The streamlined and continuously improved process makes it a waste-minimizing, environmentally friendly technology. The environmental superiority of the ibuprofen technology at BASF’s Bishop site was recognized with a Kirkpatrick Achievement Award for “outstanding advances in chemical engineering technology” in 1993 and a Presidential Green Chemistry Award in 1997.
Over 20 Years Of Dedication To Production Of Ibuprofen
The BASF facility at the Bishop, Texas, site was built in 1991 and began operations on September, 1992. Since then, it has become one of the world’s most significant Ibuprofen plants. The FDA-audited and GMP-compliant production site is part of the OSHA (U.S. Department of Labor's Occupational Safety and Health Administration) Voluntary Protection Program (VPP) and is recognized with the “VPP Star site” status. The VPP recognizes employers and workers in the private industry and federal agencies who have implemented effective safety and health management systems.
Innovation With Ibuprofen DC 85 – For Direct Compression
Today BASF produces several ibuprofen grades at its Bishop site including the API for the process-accelerating Ibuprofen DC 85 product, which has been specifically designed for direct compression into tablets. With Ibuprofen DC 85, BASF solved two of the most common industry challenges in direct compression of ibuprofen: persistent sticking to the machinery and the need for high concentration of drug substances. Ibuprofen DC 85 maximizes production speed while minimizing stickiness. The result is a reliable fault-free tableting production with higher output rates. Furthermore, expensive wet granulation and compaction processing steps are not needed, which reduces production costs.